The Influence of Psychosocial Dysfunctions in Chronic Schizophrenia Patients in Remission: A Hospital-Based Study

Swain, Sarada Prasanna; Behura, Sushree Sangita; Dash, Muktikesh; Nayak, Anil Kumar; Pati, Saswati Sucharita

doi:10.4103/0253-7176.203120

Cited by 5 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 1 Symptoms have wide-ranging impacts on a person’s daily life, with substantial detrimental impacts on social, personal, vocational, and/or familial activities. 2 Schizophrenia has been ranked among the top 25 leading causes of disability worldwide. 3 Prevalence ranges from 0.2% to 2.6% in the European Union, 4 and global estimates vary from 0.3% to 0.7%.…”

Section: Introductionmentioning

confidence: 99%

Quantifying the treatment goals of people recently diagnosed with schizophrenia using best–worst scaling

Bridges¹,

Beusterien²,

Heres³

et al. 2018

PPA

View full text Add to dashboard Cite

ObjectiveThis study seeks to quantify the treatment goals of people recently diagnosed with schizophrenia and explore their impact on treatment plan.MethodsPeople aged 18–35 years with a confirmed diagnosis of schizophrenia within the past 5 years were surveyed in the UK, Germany, and Italy. Treatment goals were assessed via a validated best–worst scaling instrument, where participants evaluated subsets of 13 possible treatment goals identified using a balanced incomplete block design. Participants identified the most and least important goals within each task. Data were also collected on current treatment and preference for daily oral versus long-acting injectable (LAI) treatment. Hierarchical Bayes was used to identify preference weights for the goals, and latent class analysis was used to identify segments of people with similar goals. The segments were compared with the current treatment and preference for oral versus LAI treatment.ResultsAcross 100 participants, the average age was 26 years, 75% were male and 50% were diagnosed within 2 years ago. Overall, preferences were most favorable for reduced disease symptoms, think clearly, reduced hospitalizations, reduced anxiety, and take care of self. A total of 61% preferred oral medication and 39% LAI. Two groups were identified with different treatment goals; 50% of participants emphasized clinical goals, including reduced disease symptoms (preference weight =19.7%), reduced hospitalizations (15.5%), and reduced anxiety (10.5%). The other 50% emphasized functional goals, including improved relationships with family/friends (11.4%), increased interest in work (10.6%), experiencing a fuller range of emotions (8.4%), and ability to socialize (7.5%). Those emphasizing functional goals were more likely to be on LAI (44% versus 26%; p=0.059) and preferred LAI (46% versus 32%; p=0.151).ConclusionsPeople with recent-onset schizophrenia may focus more on clinical goals or functional goals, a discussion of which may help facilitate patient engagement.

show abstract

Section: Introductionmentioning

confidence: 99%

Quantifying the treatment goals of people recently diagnosed with schizophrenia using best–worst scaling

Bridges¹,

Beusterien²,

Heres³

et al. 2018

PPA

View full text Add to dashboard Cite

show abstract

“…Schizophrenia is a group of major mental diseases with unknown etiology, most of which have slow or sub acute onset in young adults (10). The prevalence rate of this disease is high, up to 6.55‰ according to domestic surveys in China, accounting for about half of the lifetime prevalence rate (13.70‰) of mental disorders except neuropathy.…”

Section: Discussionmentioning

confidence: 99%

Prediction of the significance in the improvement of depression symptoms of amisulpride in the treatment of schizophrenia: an 8-week case-control study

et al. 2020

View full text Add to dashboard Cite

Background: Aminosulpiride is a benzamide used to treat acute or chronic schizophrenia Some researchers believe that early improvement of depression symptoms in patients has a certain predictive effect on the recovery of symptoms after drug treatment for schizophrenia. This study is aimed to explore whether the improvement of depression symptoms is a predictive factor for the amelioration of the schizophrenia symptoms by amisulpride treatment.

show abstract

Development of family resource indicators for people with schizophrenic disorder in community by modified Delphi method in Beijing, China

Wang,

Jin,

et al. 2024

BMJ Open

View full text Add to dashboard Cite

IntroductionMost people with schizophrenia in China are supported by their family members in community. The patient’s family is confronted with severe care burden and pressure, which directly affects the caregiver’s own health and social life, and indirectly affects the patient’s rehabilitation. Adequate family resources can reduce the burden and pressure on families. But there is an absence of systematic family resource indicators for people with schizophrenic disorder in China.ObjectivesThis study aimed to develop a set of family resource indicators for people with schizophrenic disorder in China.DesignPreliminary family resource indicators were generated and refined by literature review and an expert consultation meeting. Two rounds of email-based Delphi survey were carried out to identify family resource indicators.SettingTwo rounds of email-based Delphi survey were performed from July to September 2021 in Beijing, China.ParticipantsThere were 15 mental health doctors from community health service centres and four psychiatrists from tertiary hospitals, and two primary care researchers from universities in the first and second rounds Delphi survey.ResultsAll the 21 experts participated in both rounds of Delphi survey. A total of 46 indicators achieved consensus for inclusion in the final set of indicators after two rounds of Delphi survey. The final set of indicators was grouped into 10 domains: financial support (three indicators), psychological and spiritual support (eight indicators), medical treatment (three indicators), information and education (three indicators), structural support (two indicators), external family resources included social resources (five indicators), cultural resources (two indicators), economic resources (seven indicators), environmental resources (four indicators) and medical resources (nine indicators).ConclusionsA set of 46 family resource indicators for people with schizophrenic disorder in community was identified by an iterative Delphi process in Beijing, China. However, the indicators still need to be validated by testing in further studies.

show abstract

The Influence of Psychosocial Dysfunctions in Chronic Schizophrenia Patients in Remission: A Hospital-Based Study

Cited by 5 publications

References 18 publications

Quantifying the treatment goals of people recently diagnosed with schizophrenia using best–worst scaling

Quantifying the treatment goals of people recently diagnosed with schizophrenia using best–worst scaling

Prediction of the significance in the improvement of depression symptoms of amisulpride in the treatment of schizophrenia: an 8-week case-control study

Development of family resource indicators for people with schizophrenic disorder in community by modified Delphi method in Beijing, China

Contact Info

Product

Resources

About

The Influence of Psychosocial Dysfunctions in Chronic Schizophrenia Patients in Remission: A Hospital-Based Study

Cited by 5 publications

References 18 publications

Quantifying the treatment goals of people recently diagnosed with schizophrenia using best&ndash;worst scaling

Quantifying the treatment goals of people recently diagnosed with schizophrenia using best&ndash;worst scaling

Prediction of the significance in the improvement of depression symptoms of amisulpride in the treatment of schizophrenia: an 8-week case-control study

Development of family resource indicators for people with schizophrenic disorder in community by modified Delphi method in Beijing, China

Contact Info

Product

Resources

About

Quantifying the treatment goals of people recently diagnosed with schizophrenia using best–worst scaling

Quantifying the treatment goals of people recently diagnosed with schizophrenia using best–worst scaling